*Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

†Department of Biostatistics for Clinical Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

‡Department of Surgery, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

§Department of Surgery, Mount Sinai Hospital, Toronto, ON, Canada

∥Sarcoma Unit, Department of Academic Surgery, Royal Marsden NHS Foundation Trust, London, United Kingdom

¶Department of Surgery, Institut Gustave Roussy, Villejuif, France

#Department of Surgery, Institut Curie, Paris, France

**Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

††Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

‡‡Department of Surgical Oncology, Princess Margaret Cancer Centre, Mount Sinai Hospital, Toronto, ON, Canada

§§Department of Surgery, University of Toronto, Toronto, ON, Canada

∥∥Department of Sarcoma and General Surgery, Midlands Abdominal and Retroperitoneal Sarcoma Unit, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom

¶¶Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Presented, in part, at the 2021 Connective Tissue Oncology Society Annual Meeting, Virtual, November 16 to 19, 2021.

The authors report no conflicts of interest.

[email protected].

Supplemental Digital Content is available for this article. Direct URL citations are provided in the HTML and PDF versions of this article on the journal's website, www.annalsofsurgery.com.